Sorry, Your Requested Page Was Not Found.
Greetings! We apologize for the inconvenience, but the page, Eyegate Pharmaceuticals Reports Full Year 2016 Financial Results And Provides Business Update is no longer available. Please use our search box below to find related content and browse the list of related news stories. Depending on the topic, news articles are deleted 3 - 18 months after the created date. We prefer to keep content fresh and current and not keep old news. Thanks for visiting today.Search RobinsPost News & Noticias
Connect Biopharma Reports Full Year 2023 Financial Results and Provides Business Update
Simcere is actively engaged with China’s Center for Drug Evaluation ... today reported financial results for the year ended December 31, 2023, and provided a business update. Read More
ASLAN Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides ...
and SINGAPORE, April 12, 2024 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals ... today announced financial results for the fourth quarter and full year ended December 31, 2023, and provided an update ... Read More
Vertex Reports First Quarter 2024 Financial Results
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the first quarter ended March 31, 2024, and reite ... Read More
flyExclusive Reports Full Year 2023 Financial Results
(NYSEAMERICAN:FLYX) today announced full year 2023 financial results through a Form 10-K ... timely file its required annual and quarterly reports with the SEC; the ability of the Company to ... Read More
Reviva Reports Full Year 2023 Financial Results and Recent Business Highlights
April 15, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings ... today reported financial results for the full year ended December 31, 2023 and summarized recent business highlights. 2023 was an ... Read More
Connect Biopharma Reports Full Year 2023 Financial Results and Provides Business Update
the in-license agreement for CBP-174 with Pfizer (originally licensed from Arena Pharmaceuticals) and postpone the advancement of all pre-clinical and discovery programs. The Company’s overall ... Read More
NANOBIOTIX Provides Business Update and Reports Full Year 2023 Financial Results
Availability of the Full Year 2023 Financial Reports The URD and 20-F are ... will briefly review the Company’s year-end results and an update on business activities before taking questions ... Read More
Pharvaris Reports Fourth Quarter And Full Year 2023 Financial Results And Provides Business Update
today reported financial results for the fourth quarter and year ended December 31, 2023 and provided a business update. “2024 is off to a strong start, supported by the incredible momentum we ... Read More
NANOBIOTIX Provides Business Update and Reports Full Year 2023 Financial Results
2023 with cash runway into Q3 2025 including the $20 million first development milestone due from Janssen 2023 Universal Registration Document filed with the French financial market authority and ... Read More
Blow Us A Whistle
Comments (Whistles) Designed By Disqus